Oncotarget

This article has an addendum. Addendum in: Oncotarget. 2023; 14:668-668.

Case Reports:

Immunerelated adverse events and atypical radiological response with checkpoint inhibitor immunotherapy in an elderly patient with high PDL1 expressing lung adenocarcinoma

PDF  |  Full Text  |  How to cite

Oncotarget. 2018; 9:33043-33049. https://doi.org/10.18632/oncotarget.25984

Metrics: PDF 2100 views  |  Full Text 2795 views

Eduard Teixidor1, Elia Sais1, Carmen Amalia Vásquez2, Walter Carbajal1, Alejandro Hernández1, Gloria Sánchez3, Angel Izquierdo1, Sara Verdura4,5, Javier A. Menéndez4,5 and Joaquim Bosch-Barrera1,5,6

1Department of Medical Oncology, Catalan Institute of Oncology, Doctor Josep Trueta University Hospital, Girona, Spain

2Department of Anatomical Pathology, Dr. Josep Trueta Hospital of Girona, Girona, Catalonia, Spain

3Department of Radiology, Diagnostic Imaging Institute, Doctor Josep Trueta University Hospital, Girona, Spain

4ProCURE (Program Against Cancer Therapeutic Resistance), Metabolism and Cancer Group, Catalan Institute of Oncology, Girona, Catalonia, Spain

5Girona Biomedical Research Institute (IDIBGi), Girona, Catalonia, Spain

6Department of Medical Sciences, Medical School, University of Girona, Girona, Spain

Correspondence to:

Joaquim Bosch-Barrera, email: [email protected]

Keywords: immunosenescence; elderly; nivolumab; lung cancer; hyperprogression

Received: January 20, 2018     Accepted: July 31, 2018     Published: August 31, 2018

ABSTRACT

Advances in immunotherapy have changed the therapeutic landscape of non-small cell lung cancer (NSCLC), extending overall survival over standard chemotherapy. However, by removing the protection against autoimmunity, immunotherapy can increase immune-related adverse events (irAEs). In addition, new patterns of radiological response have been observed in patients treated with immune checkpoint inhibitors (ICIs). We report the case of a 77 year-old patient with advanced lung adenocarcinoma, who presented three consecutive different irAEs (nephritis, hepatitis, and pneumonitis) and an atypical radiological response (partial response, dissociated response, and “disease flare”) in relation to treatment with the PD-1 inhibitor nivolumab. The role of ICIs in elderly patients, the incidence of consecutive irAEs, and the new patterns of radiological response, are also reviewed.